High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity

Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here, we isolated a...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia
Main Authors: Lynn, Rachel C, Feng, Yang, Schutsky, Keith, Poussin, Mathilde, Kalota, Anna, Dimitrov, Dimiter S, Powell, Daniel J
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4889499/
https://ncbi.nlm.nih.gov/pubmed/26898190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.35
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items